Ovarian cancer is the fifth leading cause of cancer death in women and the leading cause from gynecological malignancies.
Despite the recently improved outcomes of new chemotherapeutical agents in the therapy of ovarian cancer and the
increased 5-year survival rate, the mortality of this malignancy disease remains unchanged. Ovarian cancer therapy is often
correlated to the stage of the tumor, but the first step is usually surgical treatment. Afterward, various courses of chemotherapy
and radiation are suggested. Obviously, the higher the developmental stage of the tumor, the less the probability is in eradicating
it surgically, especially in relation to metastasis. It is clear that an early diagnosis of ovarian cancer is important for the survival of
these patients. In order to identify ovarian cancer patients in the early stages, a number of studies are focusing on a particular class
of antigens called cancer testis antigens. These antigens display high expression in tumors of different histology, but are normally
restricted to the testis and have low or no expression in normal tissues. In the past few years, these antigens were demonstrated to
be very promising for the early diagnosis and development of vaccines for ovarian cancer. This study aims to underline the most
reliable cancer testis antigens under investigation at this moment.
Ovarian Cancer; Cancer testis Antigens; Cancer Vaccine
Maurizio Chiriva Internati completed his degree in biological sciences at the University of Milan, Italy and doctorates of immunology at the University
of Nottingham, United Kingdom and morphological sciences at the University of Milan, Italy. He completed his postdoctoral research on tumor
immunology, virology and cancer vaccine studies from the University of Arkansas for Medical Sciences. Currently, he is the director of Basic and
Translational Research at the division on Hematology & Oncology at the Texas Tech University Health Sciences Center, School of Medicine, and is
a senior editor for the journal, International Reviews of Immunology. He has published more than 100 papers in peer reviewed journals and serves
as on the editorial board of several reputed cancer journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals